Article PDF
References
Flowers, C.R. & Melmon, K.L. Clinical investigators as critical determinants in pharmaceutical innovation. Nature Medicine 3, 136–143 (1997).
Stähelin, H.F. The history of cyclosporin A (Sandim-muneR) revisited: another point of view. Experientia 52, 5–13 (1996).
Borel, J.F., Feurar, C., Gubler, H.U. & Stäahelin, H. Biological effects of cyclosporin A: a new antily phocytic agent. Agents & Actions 6, 468–475 (1976).
Lazary, S. & Stähelin, H. Immunosuppressive and specific antimitotic effects of ovalicin. Experientia 24, 1171–1173 (1968).
Stähelin, H.F. & Von Wartburg, A. The chemical and biological route from podophyllotoxin glucoside to etopo-side: ninth Cain Memorial Award Lecture. Cancer Res. 51, 5–15 (1991).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Flowers, C., Melmon, K. Cyclosporin and the clinical investigator. Nat Med 3, 590 (1997). https://doi.org/10.1038/nm0697-590b
Issue Date:
DOI: https://doi.org/10.1038/nm0697-590b